SARS-CoV-2 Antibody Seroprevalence in a Large Neuroimmunological Patient Cohort
Overview
Authors
Authors
Affiliations
Affiliations
Soon will be listed here.
References
1.
Sharifian-Dorche M, Sahraian M, Fadda G, Osherov M, Sharifian-Dorche A, Karaminia M
. COVID-19 and disease-modifying therapies in patients with demyelinating diseases of the central nervous system: A systematic review. Mult Scler Relat Disord. 2021; 50:102800.
PMC: 7845520.
DOI: 10.1016/j.msard.2021.102800.
View
2.
van Kempen Z, Strijbis E, Al M, Steenhuis M, Uitdehaag B, Rispens T
. SARS-CoV-2 Antibodies in Adult Patients With Multiple Sclerosis in the Amsterdam MS Cohort. JAMA Neurol. 2021; 78(7):880-882.
PMC: 8087977.
DOI: 10.1001/jamaneurol.2021.1364.
View
3.
Zilla M, Wheeler B, Keetch C, Mitchell G, McBreen J, Wells A
. Variable Performance in 6 Commercial SARS-CoV-2 Antibody Assays May Affect Convalescent Plasma and Seroprevalence Screening. Am J Clin Pathol. 2020; 155(3):343-353.
PMC: 7665309.
DOI: 10.1093/ajcp/aqaa228.
View
4.
Pritsch M, Radon K, Bakuli A, Le Gleut R, Olbrich L, Noller J
. Prevalence and Risk Factors of Infection in the Representative COVID-19 Cohort Munich. Int J Environ Res Public Health. 2021; 18(7).
PMC: 8038115.
DOI: 10.3390/ijerph18073572.
View
5.
Joseph L, Gyorkos T, Coupal L
. Bayesian estimation of disease prevalence and the parameters of diagnostic tests in the absence of a gold standard. Am J Epidemiol. 1995; 141(3):263-72.
DOI: 10.1093/oxfordjournals.aje.a117428.
View